{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelioma%3B+Pleura", "query": { "condition": "Mesothelioma; Pleura" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 119, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelioma%3B+Pleura&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:32:35.288Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03907852", "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Mesothelioma, Malignant", "Mesothelioma; Pleura", "Mesotheliomas Pleural", "Mesothelioma Peritoneum", "Cholangiocarcinoma", "Cholangiocarcinoma Recurrent", "Ovarian Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "High Grade Ovarian Serous Adenocarcinoma" ], "interventions": [ { "name": "gavo-cel", "type": "BIOLOGICAL" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TCR2 Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2019-04-15", "completion_date": "2028-11-02", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 10, "location_summary": "San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907852" }, { "nct_id": "NCT00738582", "title": "An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "MORAb-009 (Amatuximab)", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2008-12-31", "completion_date": "2014-01-10", "has_results": true, "last_update_posted_date": "2022-09-22", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 12, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738582" }, { "nct_id": "NCT04158141", "title": "Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pleural Biphasic Mesothelioma", "Pleural Epithelioid Mesothelioma", "Stage I Pleural Malignant Mesothelioma AJCC v8", "Stage IA Pleural Malignant Mesothelioma AJCC v8", "Stage IB Pleural Malignant Mesothelioma AJCC v8", "Stage II Pleural Malignant Mesothelioma AJCC v8", "Stage IIIA Pleural Malignant Mesothelioma AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Decortication", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Pencil beam scanning proton therapy", "type": "RADIATION" }, { "name": "Pleurectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2020-01-29", "completion_date": "2023-11-20", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 12, "location_summary": "Coral Gables, Florida • Chicago, Illinois • Rochester, Minnesota + 7 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04158141" }, { "nct_id": "NCT02004028", "title": "Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "VS-6063", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2013-12-12", "completion_date": "2019-06-19", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02004028" }, { "nct_id": "NCT01675765", "title": "Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "Immunotherapy plus chemotherapy", "type": "BIOLOGICAL" }, { "name": "Immunotherapy with cyclophosphamide plus chemotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aduro Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2014-09-03", "completion_date": "2019-08-19", "has_results": true, "last_update_posted_date": "2020-09-30", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 5, "location_summary": "San Francisco, California • Tampa, Florida • Chicago, Illinois + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01675765" }, { "nct_id": "NCT00005636", "title": "Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-11", "completion_date": "2000-11", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 3, "location_summary": "New Brunswick, New Jersey • New York, New York • Cleveland, Ohio", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005636" }, { "nct_id": "NCT06756035", "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelin-Expressing Tumors", "Epithelial Ovarian Cancer", "Malignant Pleural Mesothelioma, Advanced", "Malignant Peritoneal Mesothelioma, Advanced", "Pancreatic Adenocarcinoma Advanced or Metastatic", "Lung Adenocarcinoma Metastatic", "Cholangiocarcinoma Advanced", "Cholangiocarcinoma Non-resectable", "Mesothelin-expressing Advanced Cancers", "Mesothelin-positive Advanced Malignant Solid Tumors", "Colorectal Cancer" ], "interventions": [ { "name": "CT-95", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Context Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-03-31", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 7, "location_summary": "Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06756035" }, { "nct_id": "NCT00037817", "title": "Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Esophageal Cancers", "Primary Small Cell Lung Cancers", "Non-Small-Cell Lung Carcinoma", "Pleural Mesotheliomas", "Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Depsipeptide", "type": "BIOLOGICAL" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2002-05-17", "completion_date": "2009-11-09", "has_results": false, "last_update_posted_date": "2019-09-30", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00037817" }, { "nct_id": "NCT01870609", "title": "Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "defactinib (VS-6063)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2013-09", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 12, "location_summary": "San Francisco, California • Weston, Florida • Chicago, Illinois + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01870609" }, { "nct_id": "NCT05425576", "title": "OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "OT-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotelic Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2025-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-05-21T22:32:35.288Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05425576" } ] }